Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
Expands bioprocessing footprint across Asia
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Subscribe To Our Newsletter & Stay Updated
